Viridian Therapeutics to sell series B convertible preferred stock

By Abigail W. Adams

Portland, Me., Sept. 20 – Viridian Therapeutics Inc. plans to sell series B convertible preferred stock, according to a 424B5 filing with the Securities and Exchange Commission.

Jefferies LLC, SVB Leerink LLC and Evercore ISI are bookrunners for the registered offering.

The preferred stock will be convertible into 66.67 shares of common stock, subject to the beneficial ownership limitation.

The series B preferred stock is pricing alongside a secondary offering of common stock.

Proceeds from the concurrent offerings will be used to fund the development of some drug candidates and for general corporate purposes.

Viridian is a Waltham, Mass.-based biotechnology company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.